• Je něco špatně v tomto záznamu ?

Targeted Reversible Covalent Modification of a Noncatalytic Lysine of the Krev Interaction Trapped 1 Protein Enables Site-Directed Screening for Protein-Protein Interaction Inhibitors

KR. Francisco, J. Bruystens, C. Varricchio, S. McCurdy, J. Wu, MA. Lopez-Ramirez, M. Ginsberg, CR. Caffrey, A. Brancale, AR. Gingras, MS. Hixon, C. Ballatore

. 2023 ; 6 (11) : 1651-1658. [pub] 20231009

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23022544

The covalent reversible modification of proteins is a validated strategy for the development of probes and candidate therapeutics. However, the covalent reversible targeting of noncatalytic lysines is particularly challenging. Herein, we characterize the 2-hydroxy-1-naphthaldehyde (HNA) fragment as a targeted covalent reversible ligand of a noncatalytic lysine (Lys720) of the Krev interaction trapped 1 (KRIT1) protein. We show that the interaction of HNA with KRIT1 is highly specific, results in prolonged residence time of >8 h, and inhibits the Heart of glass 1 (HEG1)-KRIT1 protein-protein interaction (PPI). Screening of HNA derivatives identified analogs exhibiting similar binding modes as the parent fragment but faster target engagement and stronger inhibition activity. These results demonstrate that HNA is an efficient site-directing fragment with promise in developing HEG1-KRIT1 PPI inhibitors. Further, the aldimine chemistry, when coupled with templating effects that promote proximity, can produce a long-lasting reversible covalent modification of noncatalytic lysines.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23022544
003      
CZ-PrNML
005      
20240116163054.0
007      
ta
008      
240105s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acsptsci.3c00156 $2 doi
035    __
$a (PubMed)37974623
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Francisco, Karol R $u Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
245    10
$a Targeted Reversible Covalent Modification of a Noncatalytic Lysine of the Krev Interaction Trapped 1 Protein Enables Site-Directed Screening for Protein-Protein Interaction Inhibitors / $c KR. Francisco, J. Bruystens, C. Varricchio, S. McCurdy, J. Wu, MA. Lopez-Ramirez, M. Ginsberg, CR. Caffrey, A. Brancale, AR. Gingras, MS. Hixon, C. Ballatore
520    9_
$a The covalent reversible modification of proteins is a validated strategy for the development of probes and candidate therapeutics. However, the covalent reversible targeting of noncatalytic lysines is particularly challenging. Herein, we characterize the 2-hydroxy-1-naphthaldehyde (HNA) fragment as a targeted covalent reversible ligand of a noncatalytic lysine (Lys720) of the Krev interaction trapped 1 (KRIT1) protein. We show that the interaction of HNA with KRIT1 is highly specific, results in prolonged residence time of >8 h, and inhibits the Heart of glass 1 (HEG1)-KRIT1 protein-protein interaction (PPI). Screening of HNA derivatives identified analogs exhibiting similar binding modes as the parent fragment but faster target engagement and stronger inhibition activity. These results demonstrate that HNA is an efficient site-directing fragment with promise in developing HEG1-KRIT1 PPI inhibitors. Further, the aldimine chemistry, when coupled with templating effects that promote proximity, can produce a long-lasting reversible covalent modification of noncatalytic lysines.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bruystens, Jessica $u Department of Pharmacology, University of California, San Diego, California 92161, United States
700    1_
$a Varricchio, Carmine $u School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF103NB, U.K $1 https://orcid.org/0000000216734768
700    1_
$a McCurdy, Sara $u Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
700    1_
$a Wu, Jian $u Department of Pharmacology, University of California, San Diego, California 92161, United States
700    1_
$a Lopez-Ramirez, Miguel A $u Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States $u Department of Pharmacology, University of California, San Diego, California 92161, United States
700    1_
$a Ginsberg, Mark $u Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
700    1_
$a Caffrey, Conor R $u Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
700    1_
$a Brancale, Andrea $u School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF103NB, U.K $u Vysoká Sk̆ola Chemicko-Technologická v Praze, Department of Organic ChemistryTechnická 5, Prague 16628, Czech Republic $1 https://orcid.org/0000000297283419
700    1_
$a Gingras, Alexandre R $u Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States
700    1_
$a Hixon, Mark S $u Mark S. Hixon Consulting LLC, 11273Spitfire Road, San Diegom California 92126, United States
700    1_
$a Ballatore, Carlo $u Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States $1 https://orcid.org/0000000227183850
773    0_
$w MED00210754 $t ACS pharmacology & translational science $x 2575-9108 $g Roč. 6, č. 11 (2023), s. 1651-1658
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37974623 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240105 $b ABA008
991    __
$a 20240116163051 $b ABA008
999    __
$a ok $b bmc $g 2036318 $s 1208989
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 6 $c 11 $d 1651-1658 $e 20231009 $i 2575-9108 $m ACS pharmacology & translational science $n ACS Pharmacol Transl Sci $x MED00210754
LZP    __
$a Pubmed-20240105

Najít záznam

Citační ukazatele

Možnosti archivace